v3.22.2.2
Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 4,503,081 $ 12,264,736
Unbilled receivable 140,813 441,721
Right-of-use asset 35,313 24,721
Prepaid expenses and other current assets 2,983,071 2,931,415
Total current assets 7,662,278 15,662,593
Property and equipment, net
Other assets 627,550 754,756
Total assets 8,289,828 16,417,349
Current liabilities:    
Accounts payable 1,285,514 301,104
Accrued expenses and other liabilities 2,236,273 3,407,533
Payable to related parties 800,000
Lease liability 35,403 24,874
Notes payable and accrued interest ($7,199,135 and $12,358,886 at fair value at September 30, 2022 and December 31, 2021, respectively) 7,552,774 12,748,155
Total current liabilities 11,909,964 16,481,666
Long-term liabilities:    
Notes payable, net of current portion (at fair value) 1,386,967 4,440,951
Other long-term liabilities 1,414,829 3,652,790
Total long-term liabilities 2,801,796 8,093,741
Total liabilities 14,711,760 24,575,407
Commitments and contingencies (Note 6)
Stockholders’ deficit    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at September 30, 2022 (unaudited) and December 31, 2021
Common stock, $0.0001 par value, 250,000,000 and 150,000,000 shares authorized at September 30, 2022 and December 31, 2021; 2,208,446 and 1,233,148 shares issued at September 30, 2022 (unaudited) and December 31, 2021, respectively; 2,207,458 and 1,232,160 shares outstanding at September 30, 2022 (unaudited) and December 31, 2021, respectively 221 124
Additional paid-in capital 99,314,436 77,967,200
Accumulated deficit (105,409,155) (85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ deficit (6,094,498) (7,878,243)
Noncontrolling interests in stockholders’ deficit (327,434) (279,815)
Total stockholders’ deficit (6,421,932) (8,158,058)
Total liabilities and stockholders’ deficit $ 8,289,828 $ 16,417,349

Source